Sansregret, Laurent
Vanhaesebroeck, Bart
Swanton, Charles
Article History
First Online: 3 January 2018
Competing interests
: L.S. became a full-time employee of Novartis after submission of this manuscript. B.V. has acted as a consultant of Karus Therapeutics. In the past 36 months, C.S. has acted as a consultant and speaker for Boehringer Ingelheim, Novartis, and Roche, has acted as a speaker for Celgene, Eli Lilly, GlaxoSmithKline, Pfizer, and Servier, serves as an advisory board member for and retains stock options in ApoGen Biotechnologies, Epic Sciences, and GRAIL, has served as an advisory board member and receives honoraria from Natera, and is the founder of, and retains stock options in, Achilles Therapeutics.